Vertex Pharmaceuticals (NQ:VRTX)

Over the past six months, Vertex Pharmaceuticals’s stock price fell to $413.23. Shareholders have lost 12.5% of their capital, which is disappointing considering the S&P 500 has climbed by 34.7%. This...

Topics Economy

Vertex Pharmaceuticals (VRTX): Buy, Sell, or Hold Post Q2 Earnings?

October 08, 2025

Tariffs aren't likely to weigh on growth at these companies.

Topics Stocks

Worried About Tariffs? 2 Safe Haven Stocks to Buy on the Dip With $500 ↗

October 07, 2025

Topics Government Stocks World Trade

Vertex to Announce Third Quarter 2025 Financial Results on November 3rd

October 06, 2025

From Vertex Pharmaceuticals Incorporated

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years ↗

October 06, 2025

Via Benzinga

1 Healthcare Stock with Exciting Potential and 2 Facing Challenges

October 06, 2025

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But financial performance has lagged recently as players offloaded surplus COVID...

The market is sleeping on these stocks, but you don't have to.

Topics Stocks

2 Beaten-Down Stocks Primed for a Comeback ↗

October 05, 2025

Jason Snipe likes ServiceNow (NOW), down 14% YTD. Morgan Stanley upgraded to Overweight. Shannon Saccocia chose iShares Core S&P Small-Cap ETF. Jim Lebenthal recommends Vertex Pharmaceuticals (VRTX).

ServiceNow, Vertex Pharmaceuticals And More: CNBC's 'Final Trades' ↗

October 03, 2025

Via Benzinga

Topics ETFs Stocks

Navigating the Future: Unlocking Investment Opportunities in High-Growth Sectors

October 04, 2025

As of October 2025, the global financial markets are undergoing a profound transformation, driven by an accelerating wave of technological innovation and a pressing global imperative for...

Via MarketMinute

Topics Artificial Intelligence Climate Change Economy

Apple To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Thursday ↗

October 02, 2025

Via Benzinga

Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design

October 02, 2025

London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented...

Via TokenRing AI

Topics Artificial Intelligence

Healthcare Sector Defies Headwinds, Rallies on Wall Street Amidst Shutdown and Jobs Data

October 01, 2025

New York, NY – October 1, 2025 – In a surprising turn of events on Wall Street today, the healthcare sector emerged as the undisputed leader, shrugging off the dual anxieties of a U.S. government...

Via MarketMinute

Topics Artificial Intelligence Economy Intellectual Property

10 Health Care Stocks Whale Activity In Today's Session ↗

October 01, 2025

Via Benzinga

What Does the Market Think About Vertex Pharmaceuticals Inc? ↗

September 30, 2025

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

September 29, 2025

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

2 S&P 500 Stocks to Research Further and 1 We Avoid

September 29, 2025

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some...

These five stocks are underperforming the S&P 500 in 2025, but have what it takes to reward investors over the long term.

Topics Stocks

5 Top Stocks to Buy in October ↗

September 28, 2025

President Donald Trump threatened 100% tariffs on some drug imports.

Topics Stocks

Pharma Tariffs Back In Spotlight On New Trump Threat ↗

September 26, 2025

Via Investor's Business Daily

Topics ETFs Government World Trade

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday ↗

September 25, 2025

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Via Benzinga

Assessing Vertex Pharmaceuticals: Insights From 15 Financial Analysts ↗

September 25, 2025

Ratings for Vertex Pharmaceuticals (NASDAQ: VRTX) were provided by 15 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.

Via Benzinga

Vertex Announces Key Advancements Across Kidney Portfolio

September 25, 2025

From Vertex Pharmaceuticals Incorporated

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings...

This Chewy Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗

September 25, 2025

Via Benzinga

My 3 Favorite Stocks to Buy Right Now ↗

September 25, 2025

Uncertainty is in the air. But these stocks inspire confidence.

Vertex Pharmaceuticals (VRTX) is a top GARP stock, offering strong revenue growth, high profitability, and a debt-free balance sheet at a reasonable valuation.

Topics Artificial Intelligence Economy

Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Emerges as a Top GARP Stock ↗

September 24, 2025

Via Chartmill

Vertex Partners with Basketball World Champion Jayson Tatum to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe-Acute Pain

September 23, 2025

From Vertex Pharmaceuticals Incorporated

Unpacking Q2 Earnings: Vertex Pharmaceuticals (NASDAQ:VRTX) In The Context Of Other Therapeutics Stocks

September 22, 2025

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Vertex...

There is a "for sale" sign on the sector, and these two stocks look particularly attractive at their current levels.

Topics Artificial Intelligence

Healthcare Stocks Are at an Historic Low and a Turnaround Is on the Horizon ↗

September 20, 2025

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.

Topics Government Intellectual Property World Trade

My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years ↗

September 18, 2025

Via Benzinga

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Transfusion-Dependent Beta Thalassemia and Sickle Cell Disease in Italy

September 18, 2025

From Vertex Pharmaceuticals